Business
ACT: Record EBITDA margin and strong specialty growth, with major CapEx fueling future expansion
ACT: Record EBITDA margin and strong specialty growth, with major CapEx fueling future expansion
About this update from Alzchem Group Ag
Sales and EBITDA grew year-over-year, driven by specialty chemicals and strong creatine demand, with record margins and robust cash flow. Major investments in creatine and defense capacity set the stage for double-digit growth from 2027. Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.